Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellebrite DI Ltd.CLBT · Entity 4238 | Chief Marketing Officer | August 24, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellebrite DI Ltd.
Report date August 24, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary shares, par value NIS 0.00001SEC Table I · non-derivative | Direct | 135,281 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 4,323 · Balance 135,281 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 25, 2026 20:09 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 4,323 | $11.36 | $49,111.44 |
DisclosureSEC source: 0001628280-26-058874 · wk-form4_1787688540.xml · nonDerivative · entry 1 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,281 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 20:09 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 2,198 | $11.24 | $24,709.04 |
DisclosureSEC source: 0001628280-26-058628 · wk-form4_1787602140.xml · nonDerivative · entry 1 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,604 F1 · kind: The shares reported as disposed herein were granted on May 20, 2024, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.16 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 12:05 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 230 | $16.07 | $3,695.59 |
DisclosureSEC source: 0001628280-26-056491 · wk-form4_1786622717.xml · nonDerivative · entry 1 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,802 F1 · kind: The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.0086 to $16.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:06 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 3,430 | $13.15 | $45,093.52 |
DisclosureSEC source: 0001628280-26-038069 · wk-form4_1779825960.xml · nonDerivative · entry 2 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,032 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.98 to $13.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:06 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 2,243 | $13.10 | $29,383.30 |
DisclosureSEC source: 0001628280-26-038069 · wk-form4_1779825960.xml · nonDerivative · entry 1 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,462 F1 · shares: The shares reported as disposed herein were granted on May 20, 2024, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:08 UTC | Cellebrite DI Ltd. CLBT · Entity 4238 | SaleOrdinary shares, par value NIS 0.00001 | 228 | $13.01 | $2,966.28 |
DisclosureSEC source: 0001628280-26-035095 · wk-form4_1778789278.xml · nonDerivative · entry 1 GEE DAVID NICHOLAS · CIK 0001547134 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,705 F1 · shares: The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.84 to $13.175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.